UFP Technologies, Inc.
- Open
- 251.76
- Day high
- 258.13
- Day low
- 249.00
- Prev close
- 255.03
- Volume
- 118K
- Mkt cap
- $2.0B
- P/E (TTM)
- 28.6
- EPS (TTM)
- $8.90
- P/B
- 4.5
- P/S
- 3.2
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$922K over the last 3 months (0 open-market buys, 3 sales)
- 🏛Institutions mixed (13F)
UFP Technologies, Inc. (UFPT) is a Healthcare company listed on NASDAQ. The stock is up 11% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 3 sales (SEC Form 4).
UFP Technologies, Inc. (UFPT) financials & analyst ratings
Fundamentals (TTM)
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
UFPT earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 5, 2026 | $2.18 | $2.48 | +13.8% | $154M | -0.4% |
| Feb 25, 2026 | $2.26 | $2.44 | +8.0% | $149M | -3.6% |
| Jul 31, 2024 | $1.53 | $1.75 | +14.4% | $110M | +3.0% |
| May 1, 2024 | $1.10 | $1.64 | +49.1% | $105M | +7.9% |
| Feb 21, 2024 | $1.14 | $1.51 | +32.5% | $101M | +7.3% |
| Nov 1, 2023 | $1.52 | $1.52 | +0.0% | $101M | +6.9% |
| Aug 1, 2023 | $1.42 | $1.55 | +9.2% | $100M | +2.1% |
| May 2, 2023 | $1.04 | $4.20 | +303.8% | $98M | +9.7% |
| Mar 7, 2023 | $0.91 | $1.10 | +20.9% | $91M | +5.1% |
| Nov 2, 2022 | $0.95 | $0.51 | -46.3% | $97M | +13.7% |
| Aug 2, 2022 | $0.74 | $1.17 | +58.1% | $94M | +24.3% |
| May 4, 2022 | $0.45 | $0.64 | +42.2% | $71M | +11.0% |
UFPT insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jun 15, 2026 | FELDMANN CYNTHIA Ldirector | Sell | 100 | $240.40 |
| Jun 15, 2026 | FELDMANN CYNTHIA Ldirector | Option | 1,200 | $43.95 |
| Jun 15, 2026 | FELDMANN CYNTHIA Ldirector | Sell | 1,100 | $239.19 |
| Jun 8, 2026 | FELDMANN CYNTHIA Ldirector | Grant | 802 | — |
| Jun 8, 2026 | BAILLY R JEFFREYdirector, officer: Executive Chairman | Tax | 750 | $223.87 |
| Jun 8, 2026 | OBERDORF THOMASdirector | Grant | 802 | — |
| Jun 8, 2026 | KOZIN MARC Ddirector | Grant | 802 | — |
| Jun 8, 2026 | Stafford Ryan Kofficer: SVP Human Resources | Grant | 1,448 | — |
| Jun 8, 2026 | ROCK MITCHELLofficer: President | Grant | 2,895 | — |
| Jun 8, 2026 | BAILLY R JEFFREYdirector, officer: Executive Chairman | Grant | 1,787 | — |
| Jun 8, 2026 | CROTEAU DANIEL Cdirector | Grant | 802 | — |
| Jun 8, 2026 | Hassett Joseph Johndirector | Grant | 802 | — |
| Jun 8, 2026 | LATAILLE RONALD Jofficer: Chief Financial Officer | Grant | 4,454 | — |
| Jun 8, 2026 | Hudson Symeriadirector | Grant | 802 | — |
| May 13, 2026 | CROTEAU DANIEL Cdirector | Sell | 2,864 | $221.71 |
Source: UFPT SEC Form 4 filings, latest Jun 15, 2026. For informational purposes only — not investment advice.
See the full UFPT insider & 13F page →UFP Technologies, Inc. company profile
Overview
UFP Technologies, Inc. (NASDAQ:UFPT) is a specialized manufacturing company founded in 1963 and headquartered in Newburyport, Massachusetts. The company went public in 1993 and has evolved from a general foam and plastics manufacturer into a focused provider of engineered components and packaging solutions, with particular strength in the medical device industry. UFP Technologies designs and custom manufactures components, subassemblies, products, and packaging using specialized foams, films, and plastics, serving customers across medical, automotive, aerospace, consumer, and industrial markets.
Business
UFP Technologies operates as a contract manufacturer specializing in converting raw materials—primarily foams, films, and plastics—into finished components and packaging solutions for other companies' products. The company's expertise lies in precision die-cutting, thermoforming, fabrication, and assembly of these materials into custom-engineered solutions. The medical market represents UFP's largest and fastest-growing segment, accounting for approximately 91% of total revenue based on recent quarters ($135.4 million of $148.1 million in Q1 2025). Within healthcare, the company produces single-use and single-patient devices and components used across multiple medical applications. Key medical segments include safe patient handling (their second-largest and fastest-growing segment with 50% growth), infection prevention products, minimally invasive surgery components, wearables, orthopedic soft goods, orthopedic implant packaging, interventional and surgical devices, and robotic surgery components. These products are critical components that enable medical device manufacturers to deliver sterile, safe, and effective healthcare solutions. The all other markets segment comprises the remaining 9% of revenue ($12.7 million in Q1 2025) and includes automotive interior trim, aerospace and defense applications like military uniform components, consumer products such as athletic padding and abrasive nail files, electronics packaging, industrial air filtration systems, and protective cases. This diversification provides some stability against medical market fluctuations, though the company has clearly prioritized medical market growth given its higher margins and growth potential.
Competitive moat
UFP Technologies possesses a moderate competitive moat built primarily on customer relationships, specialized manufacturing capabilities, and regulatory expertise rather than proprietary technology or patents. The company's strongest moat characteristics include deep integration with medical device customers through long-term exclusive manufacturing agreements, specialized knowledge of medical device regulatory requirements and quality standards, and established manufacturing processes that are difficult and costly for customers to replicate in-house. The customer switching costs provide meaningful protection, as medical device manufacturers face significant regulatory hurdles, validation requirements, and potential supply chain disruption when changing component suppliers. UFP's exclusive manufacturing agreements, such as the recent safe patient handling contract extending through mid-2030, create multi-year revenue visibility and competitive protection. The company's expertise in navigating FDA regulations and maintaining ISO certifications creates barriers for new entrants lacking this specialized knowledge. However, UFP's moat has notable limitations. The company primarily serves as a contract manufacturer rather than owning proprietary technologies or patents, making it potentially vulnerable to customer decisions to bring manufacturing in-house or switch to competitors. The manufacturing processes, while specialized, are not impossible to replicate given sufficient investment. Competitive threats include larger contract manufacturers with greater scale economies, customers developing in-house capabilities, and new entrants offering lower-cost alternatives. The medical device industry's ongoing consolidation could also strengthen customer bargaining power over time. While UFP has built strong customer relationships and operational expertise, the moat is more operational than structural, requiring continuous investment in capabilities and customer service to maintain competitive advantages.
Risks & safety
UFP Technologies demonstrates a strong margin of safety with healthy financial metrics and conservative capital structure, though valuation appears elevated relative to historical norms. • Liquidity and Solvency: Strong current ratio of 2.58x, minimal debt with debt-to-equity ratio of just 0.046, and positive free cash flow generation of $11.0 million in Q1 2025 indicate low financial risk • Cash Generation: Consistent positive operating cash flow of $13.8 million in Q1 2025, with management paying down approximately $7 million in debt and maintaining leverage below 1.5x • Valuation Metrics: Current P/E ratio of 22.6x appears reasonable for growth profile, though EV/EBITDA of 16.8x suggests premium valuation; Graham number of $48.57 indicates stock trading well above conservative value metrics • Growth Quality: Revenue growth of 41% in Q1 2025 driven by organic expansion rather than excessive leverage or unsustainable practices • Other Considerations: Concentrated customer base in medical devices creates some revenue concentration risk, though long-term exclusive contracts provide stability; minimal international exposure reduces currency and geopolitical risks
Recent development
Over the past few years, UFP Technologies has executed a clear strategic pivot toward higher-margin medical applications while maintaining operational excellence across all segments. The most significant development has been the company's aggressive expansion in the safe patient handling market, which became their second-largest segment with 50% growth in Q1 2025. This growth was anchored by securing a key customer agreement providing exclusive manufacturing rights through mid-2030, demonstrating UFP's ability to win long-term strategic partnerships. The company has invested heavily in manufacturing capacity expansion, particularly in their Dominican Republic facility, to support growing medical device demand. They completed a strategic acquisition in St. Charles, Illinois, to add complementary capabilities and are actively exploring additional acquisition opportunities, particularly in injection molding technologies that could expand their service offerings to existing customers. In the robotic surgery segment, UFP is launching two new programs in the second half of 2025, positioning the company to benefit from the continued growth in minimally invasive surgical procedures. The infection prevention segment continues expanding with new product development, while the interventional and surgical business has recovered from previous customer destocking challenges. Management has also focused on operational efficiency improvements and debt reduction, paying down approximately $7 million in debt during Q1 2025 while maintaining strong cash generation capabilities.
UFPT company profile · for informational purposes only — not investment advice.
Track UFPT with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free